HCDP Manchester

AML MRD Monitoring Overview

Home

(Based on NHS England Genomic Unit Guidelines) Dillon et al and ELN DAVID 2025

Use the links below to navigate to MRD recommendations:

BCR::ABL
Core binding factor (CBF)
DEK:NUP
KMT2A
No Molecular MRD
Low intensity treatment monitoring
PML::RARA
Post transplant
NPM1 mut/ FLT3 ITD
AML MRD minimum standards
FLT3 ITD (NPM1 wt)
NPM1 (without FLT3 ITD)
CEBPA biZIP (in frame)

All guidance is for routine samples. If a positive/ concerning result arises on treatment- advice will be given by genomics lab as to when to send repeat sample. It is imperative the guidance is reviewed on each individual report. These document outlines only “routine” follow-up.